0001567619-23-006225.txt : 20230525 0001567619-23-006225.hdr.sgml : 20230525 20230525151226 ACCESSION NUMBER: 0001567619-23-006225 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230525 DATE AS OF CHANGE: 20230525 EFFECTIVENESS DATE: 20230525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Salarius Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001615219 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465087339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-482643 FILM NUMBER: 23959972 BUSINESS ADDRESS: STREET 1: 2450 HOLCOMBE BLVD STREET 2: SUITE J-608 CITY: HOUSTON STATE: TX ZIP: 77021 BUSINESS PHONE: 346-772-0346 MAIL ADDRESS: STREET 1: 2450 HOLCOMBE BLVD STREET 2: SUITE J-608 CITY: HOUSTON STATE: TX ZIP: 77021 FORMER COMPANY: FORMER CONFORMED NAME: Flex Pharma, Inc. DATE OF NAME CHANGE: 20140730 D 1 primary_doc.xml X0708 D LIVE 0001615219 Salarius Pharmaceuticals, Inc. 2450 Holcombe Blvd. Suite X Houston TX TEXAS 77021 832-804-9144 DELAWARE None Flex Pharma, Inc. Corporation true Tess Burleson 2450 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director William K. McVicar 2450 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Chair Arnold C. Hanish 2450 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Paul Lammers 2450 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Jonathan Lieber 2450 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director Bruce J. McCreedy 2450 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Director David J. Arthur 2540 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Executive Officer Director President, Chief Executive Officer, Director Mark J. Rosenblum 2450 Holcombe Blvd. Suite X Houston TX TEXAS 77021 Executive Officer Chief Financial Officer Biotechnology Decline to Disclose 06b false 2023-05-11 false true true true false 0 H. C. Wainwright & Co., LLC 375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 NY NEW YORK false 6000000 6000000 0 Such amount would be $16,706,819 by including the aggregate exercise price due to the Company assuming full cash exercise of all warrants. false 1 545000 0 In connection with the private placement, the placement agent received $545,000 and warrants to purchase up to 254,545 shares of Common Stock at an exercise price per share of $2.0625 per share. 0 false Salarius Pharmaceuticals, Inc. /s/ Mark J. Rosenblum Mark J. Rosenblum Chief Financial Officer 2023-05-25